Skip to main content

Table 1 Detailed Demographic Data and Spirometric Results

From: The Bioavailability of Salbutamol in Urine via Volumatic and Nonvolumatic Valved Holding Chambers

 

Distribution

 

Variable

Total

Strata

P

Age (yr)

43.10 ± 12.99

Male: 44.93 ± 14.07

Female: 43.32 ± 12.56

0.71

Gender

N = 40

Male: 15

Female: 25

NA

Weight (kg)

68.53 ± 13.38

Male: 73.27 ± 9.26

Female: 65.68 ± 14.79

0.08

Height (cm)

163.33 ± 7.91

Male: 170.45 ± 7.70

Female: 159.04 ± 4.00

< 0.0001*

FVC† difference‡

5.34 ± 7.45

Asthm Yar: 4.75 ± 6.99

Dam Yar: 6.05 ± 8.00

0.46

FEV1† difference‡

7.39 ± 5.49

Asthm Yar: 7.54 ± 5.08

Dam Yar: 7.23 ± 5.93

0.53

PEF† difference‡

4.18 ± 13.52

Asthm Yar: 7.10 ± 13.64

Dam Yar: 1.25 ± 12.92

0.054

FEF25-75%† difference‡

16.20 ± 12.49

Asthm Yar: 16.30 ± 12.05

Dam Yar: 16.10 ± 13.06

0.92

FEF50%† difference‡

13.94 ± 11.55

Asthm Yar: 13.45 ± 11.78

Dam Yar: 14.43 ± 11.44

0.64

Preference

6.00 ± 2.58

Asthm Yar: 4.83 ± 2.38

Dam Yar: 7.18 ± 2.23

< 0.0001*

SUC (ng/mL)§

Mean: 1057.76 ± 437.86

Asthm Yar

Mean: 1188.84 ± 478.80

Minimum: 419.51

Maximum: 2471.95

Dam Yar

Mean: 926.68 ± 351.95

Minimum: 264.63

Maximum: 1787.81

0.002*

  1. *Significant differences.
  2. †As percentage of the predicted values.
  3. ‡Before and after spacer use.
  4. §Salbutamol urine concentration.
  5. FEF, forced expiratory flow; PEF, peak expiratory flow; FVC, forced vital capacity.